Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 28;9(3):648. doi: 10.3390/jcm9030648

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Survival between most popular first line regimens between the two time periods. Kaplan-Meier curves of patients who started a first line therapy with gemcitabine/nab-paclitaxel (A), mFOLFIRINOX (B) or with either one of these regimens (C) according to the year when the first systemic treatment was administered. Horizontal grid lines indicate the survival proportion of 25% and intersections with vertical grid lines indicate the survival time for the respective Kaplan-Meier curves at this point.